Altres ajuts: Spanish Agency of Medicines and Medical Devices (AEMPS); Biogen; Bristol Myers-Squibb (BMS); Celltrion Healthcare; Lilly; Merck; Novartis; Pfizer; Regeneron Pharmaceuticals; Samsung Bioepis.Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug's overall effectiveness. The objective of the study was to identify factors associated with discontinuation of ts/bDMARDs in a real-world dataset. The study population comprised patients diagnosed with RA, PsA, and AS included in the BIOBADASER registry for whom follow-up data were av...
OBJECTIVES: To assess the discontinuation of first-line biological treatment and to evaluate the rea...
The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, convent...
Objective: To examine the association of the evolution in physician-reported and patient-reported ou...
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biologi...
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biologi...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be dif...
Abstract Background The aim of this study is to evaluate the retention rates and reasons for discont...
We aim to explore real-world biological survival stratified for discontinuation reason and determine...
Objectives: To assess the discontinuation of first-line biological treatment and to evaluate the rea...
Introduction: Biologic disease-modifying antirheumatic drugs (bDMARDs) play a pivotal role in the tr...
OBJECTIVES Data from randomized controlled trials have shown the feasibility of discontinuation o...
Objective: To compare reasons for discontinuation and drug retention rates per reason among anticyto...
Ebina, K., Hashimoto, M., Yamamoto, W. et al. Correction to: Drug tolerability and reasons for disco...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be dif...
BackgroundThe aim of this study is to evaluate the retention rates and reasons for discontinuation f...
OBJECTIVES: To assess the discontinuation of first-line biological treatment and to evaluate the rea...
The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, convent...
Objective: To examine the association of the evolution in physician-reported and patient-reported ou...
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biologi...
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biologi...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be dif...
Abstract Background The aim of this study is to evaluate the retention rates and reasons for discont...
We aim to explore real-world biological survival stratified for discontinuation reason and determine...
Objectives: To assess the discontinuation of first-line biological treatment and to evaluate the rea...
Introduction: Biologic disease-modifying antirheumatic drugs (bDMARDs) play a pivotal role in the tr...
OBJECTIVES Data from randomized controlled trials have shown the feasibility of discontinuation o...
Objective: To compare reasons for discontinuation and drug retention rates per reason among anticyto...
Ebina, K., Hashimoto, M., Yamamoto, W. et al. Correction to: Drug tolerability and reasons for disco...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be dif...
BackgroundThe aim of this study is to evaluate the retention rates and reasons for discontinuation f...
OBJECTIVES: To assess the discontinuation of first-line biological treatment and to evaluate the rea...
The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, convent...
Objective: To examine the association of the evolution in physician-reported and patient-reported ou...